Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes against<i>Trichosporon asahii</i>

Sasaki, Eisuke; Tashiro, Takayoshi; Kuroki, Misuzu; Seki, Masafumi; Miyazaki, Yukiko; Maesaki, Shigefumi; Tomono, Kazunori; Kadota, Jun‐ichi; Kohno, Shigeru

doi:10.1046/j.1365-2249.2000.01134.x

Cited by 20 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incubation of macrophages with M-CSF enhances the killing of Candida spp. These in vitro data were in agreement with animal studies of invasive candidiasis, aspergillosis, and trichosporonosis, where M-CSF treatment was associated with improved survival and reduced fungal burden (Cenci et al 1991;Sasaki et al 2000;. Treatment of chronic disseminated candidiasis in rats with M-CSF has been shown to reduce the outgrowth of C. albicans.…”

Section: Hematopoietic Growth Factors (Hgf)supporting

confidence: 81%

Combating Fungal Infections

Ahmad¹,

Owais²,

Shahid³

et al. 2010

View full text Add to dashboard Cite

Section: Hematopoietic Growth Factors (Hgf)supporting

confidence: 81%

Combating Fungal Infections

Ahmad¹,

Owais²,

Shahid³

et al. 2010

View full text Add to dashboard Cite

“…Augmented effector cell function may be disease-and tissue-specific. Studies have shown that M-CSF enhanced the antifungal activity of mononuclear cells in a murine model of disseminated Trichosporon asahii infection through the induction of TNF-a [61], but it enhanced the fungicidal and phagocytic activities of splenocytes only-rather than Kupffer cells or pulmonary alveolar macrophages-in a rabbit model of disseminated candidiasis [62]. Moreover, studies of the immunomodulatory activity of M-CSF in mice have revealed complex effects, including some that are detrimental [63].…”

Section: Nonspecific Augmentative Immune Therapiesmentioning

confidence: 99%

Adjunctive Immune Therapy for Fungal Infections

Casadevall

Pirofski

2001

CLIN INFECT DIS

View full text Add to dashboard Cite

Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune responses--and thus enhance the efficacy of antifungal drugs--is a reasonable approach to improve the prognosis of fungal infections. Advances in biotechnology have produced a variety of biological response modifiers with the potential to serve as adjunctive immune therapy for the treatment of fungal infections, including cytokines, monoclonal antibodies, and cell growth factors. In recent years, immune-modulating therapies have been studied in an effort to define their potential use for the treatment of fungal infections. Much of the available information on the use of this approach is encouraging and invites further investigation--with the caveats that the information is mostly anecdotal and that immune-modulating therapy occasionally has produced adverse effects.

show abstract

“…34) In addition, a protective effect of M-CSF against fungal infection via monocytes was reported in vitro and in vivo. [35][36][37][38][39] In summary, the present findings suggest that granulocyte function should be improved to prevent infection after chemotherapy. Administration of M-CSF is effective for preventing the dysfunction of neutrophils, resulting in the prevention of febrile neutropenia following chemotherapy.…”

Section: Discussionmentioning

confidence: 88%

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy

Hidaka

Fujimura

Sakai

et al. 2001

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

There are very few studies describing the preventive effect of macrophage colony-stimulating factor (M-CSF/CSF-1) on chemotherapy-induced infection. In this study, we evaluated the changes in superoxide anion production by granulocytes before and after chemotherapy in ovarian cancer patients and investigated the preventive effect of M-CSF on chemotherapy-induced febrile neutropenia. Three courses of chemotherapy [paclitaxel 180 mg/m 2 and carboplatin (area under the curve; AUC 5)] were administered to 32 ovarian cancer patients, and seven patients presented febrile neutropenia. In the 25 afebrile patients, the percentage of superoxide anion production by granulocytes was significantly decreased from 86.5 ± ± ± ±7.7 (%) to 75.1 ± ± ± ±8.8 (%) at day 7 and 71.0 ± ± ± ±6.3(%) at day 14 without administration of CSF. However, in the patients who presented febrile neutropenia, it was more severely decreased from 86.8 ± ± ± ±6.8 (%) to 60.0± ± ± ±9.9 (%) at day 7 and 56.8 ± ± ± ±5.0 (%) at day 14 without administration of CSF. When M-CSF was administered to all patients in the next course with the same dose of chemotherapy, the incidence of febrile neutropenia was significantly decreased (P = = = =0.0195), and the duration of fever ( ≥ ≥ ≥ ≥38.0°C) and high serum C-reactive protein (CRP) ( ≥ ≥ ≥ ≥2.0 mg/dl) were also significantly shortened (P = = = =0.0023, P = = = =0.0051). Moreover, in these M-CSF-treated patients, the percentage of superoxide anion production by granulocytes was maintained at the level before chemotherapy. These findings indicate that severe impairment of granulocyte function leads to febrile neutropenia, and that M-CSF reduces the incidence of febrile neutropenia by maintaining or improving granulocyte function.

show abstract

Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes againstTrichosporon asahii

Cited by 20 publications

References 27 publications

Combating Fungal Infections

Combating Fungal Infections

Adjunctive Immune Therapy for Fungal Infections

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy

Contact Info

Product

Resources

About